The PI's long-term career goal is to become an independent and interdisciplinary researcher with a combined expertise in materials science/chemistry and cancer biology in order to develop new diagnostic and treatment modalities for cancer patients. This K25 award will provide protected time for her to receive systematic training in cancer biology. She will attend a number of biology and oncology courses/workshops and conduct lab rotations in three reputable cancer biology labs to quickly expand her knowledge and gain relevant biology lab skills. The proposed research will begin in her mentor's lab and gradually be transitioned to her own lab, where she will establish an independent cancer biology program. Her principle mentor, Dr. Chen, is a renowned surgeon and researcher in neuroendocrine (NE) cancers. NE cancers such as carcinoid, islet cell tumors, and medullary thyroid cancer are the second most common cause of isolated hepatic metastases and often cause many debilitating symptoms. While surgery is the only potentially curative therapy for patients with NE cancers, most patients present with unresectable disease. Currently, there are very limited curative and palliative treatments available to patients with NE cancers, emphasizing the need for the development of new forms of therapy. Dr. Chen's group has recently shown that the activation of Notch1 in human NE cancer cells by histone deacetylase (HDAC) inhibitors markedly suppresses tumor cell growth and NE hormone production both in vitro and in vivo.
In Aim #1 of the proposal, the PI will study the mechanism of Notch 1 mRNA induction in NE cancers via HDAC inhibitors by mapping the HDAC inhibitor-response element(s) within the Notch 1 promoter. Identifying the HDAC-response element(s) will allow for the potential development of other molecules that target this element and may also permit the development of methods to predict the clinical response of patients with NE cancer to HDAC inhibitors.
In Aim #2, whether pharmacologic activation of Notch1 using HDAC inhibitors such as valproic acid (VPA) could be a novel treatment for NE cancer patients will be determined using a murine model of recurrent/persistent or metastatic NE cancer. VPA is already used clinically in humans for treating other diseases, hence the possibility of using VPA as a viable therapeutic compound to treat NE cancers is both exciting and viable.
In Aim #3, a unique octreotide (OCT)-conjugated unimolecular micelle will be developed as a nanocarrier for hydrophobic Notch 1 activating compounds (e.g., VPA) to enhance its NE tumor-targeting abilities, thereby greatly improving its therapeutic efficacy in NE cancers while significantly reducing its various detrimental side-effects. In summary, this proposed research will lead to a better understanding of the mechanism of Notch 1 induction in NE cancers by HDAC inhibitors, which can potentially be used as therapeutic agents to treat and palliate NE cancers in affected patients. The deve- lopment of OCT-conjugated unimolecular micelles can further enhance treatment efficacy. UW-Madison is one of the top cancer research institutes in the world, thereby making it possible for the PI to achieve her goals.

Public Health Relevance

Neuroendocrine (NE) cancers are the second most common cause of isolated hepatic metastases. While surgery is the only potentially curative therapy for patients with NE cancers, most patients present with unresectable disease. Furthermore, patients will incurable NE cancers often experience debilitating symptoms that lead to a poor quality of life. This proposed research would enable the discovery of new drug compounds and nanomedicines, providing novel treatments for patients with otherwise untreatable NE cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Mentored Quantitative Research Career Development Award (K25)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Jakowlew, Sonia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
Biomedical Engineering
Biomed Engr/Col Engr/Engr Sta
United States
Zip Code
Chen, Guojun; Ma, Ben; Xie, Ruosen et al. (2018) NIR-induced spatiotemporally controlled gene silencing by upconversion nanoparticle-based siRNA nanocarrier. J Control Release 282:148-155
Wang, Bowen; Chen, Guojun; Urabe, Go et al. (2018) A paradigm of endothelium-protective and stent-free anti-restenotic therapy using biomimetic nanoclusters. Biomaterials 178:293-301
Chen, Guojun; Ma, Ben; Wang, Yuyuan et al. (2018) A Universal GSH-Responsive Nanoplatform for the Delivery of DNA, mRNA, and Cas9/sgRNA Ribonucleoprotein. ACS Appl Mater Interfaces 10:18515-18523
Chen, Guojun; Wang, Yuyuan; Xie, Ruosen et al. (2018) A review on core-shell structured unimolecular nanoparticles for biomedical applications. Adv Drug Deliv Rev 130:58-72
Chen, Guojun; Jaskula-Sztul, Renata; Esquibel, Corinne R et al. (2017) Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging. Adv Funct Mater 27:
Jaskula-Sztul, Renata; Chen, Guojun; Dammalapati, Ajitha et al. (2017) AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment. J Mater Chem B 5:151-159
Wang, Yuyuan; Wang, Yidan; Chen, Guojun et al. (2017) Quantum-Dot-Based Theranostic Micelles Conjugated with an Anti-EGFR Nanobody for Triple-Negative Breast Cancer Therapy. ACS Appl Mater Interfaces 9:30297-30305
Chen, Guojun; Shi, Xudong; Wang, Bowen et al. (2017) Unimolecular Micelle-Based Hybrid System for Perivascular Drug Delivery Produces Long-Term Efficacy for Neointima Attenuation in Rats. Biomacromolecules 18:2205-2213
Zhao, Lei; Chen, Guojun; Li, Jun et al. (2017) An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration. J Control Release 247:153-166
Chen, Guojun; Ma, Ben; Wang, Yuyuan et al. (2017) CuS-Based Theranostic Micelles for NIR-Controlled Combination Chemotherapy and Photothermal Therapy and Photoacoustic Imaging. ACS Appl Mater Interfaces 9:41700-41711

Showing the most recent 10 out of 20 publications